本文仅供信息分享,不构成用药或治疗或投资推荐。因编辑水平有限,如有错误或不是最新信息感谢指出!2月12日,国家药品监督管理局药品审评中心(CDE)官网数据表明,再鼎医药申报的瑞普替尼胶囊拟被纳入优先审评程序,其适用于 NTRK 融合基因阳性实体瘤的成年患者,此消息在生物医药领域引发广泛关注。据悉,瑞普替尼胶囊是一种酪氨酸激酶抑制剂,2024年5月,该创新药已获中国国家药品监督管理局批准,用于治疗...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.